# A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3

> **NCT00656006** · PHASE2 · COMPLETED · sponsor: **Human Genome Sciences Inc.** · enrollment: 43 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Albuferon
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00656006
- **Lead sponsor:** Human Genome Sciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2013-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00656006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00656006, "A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00656006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*